Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 15.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with high cholesterol levels either not receiving or willing and able to discontinue ongoing lipid-lowering therapy~Exclusion Criteria:~* LDL-C levels \> 250 mg/dL (6.48 mmol/L)~* Triglycerides levels \> 350mg/dL (3.95 mmol/L)~* Conditions / situations such as:~  * presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels~ * Active liver disease~ * High estimated risk of Coronary Heart Disease~ * Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease~ * Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive~* Pregnant or breast-feeding women,~* Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product~* Hypersensitivity to any component of atorvastatin~* Concurrent administration of Cytochrome P450 3A4 inhibitors (e.g. cyclosporine, erythromycin, clarithromycin, and azole antifungals) should be avoided as increasing the risk of myopathy with atorvastatin~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): AVE5530 25mg
- 3 (Type: EXPERIMENTAL): AVE5530 50mg
- 4 (Type: ACTIVE_COMPARATOR): atorvastatin 10mg
- 5 (Type: EXPERIMENTAL): atorvastatin 10mg + AVE5530 25mg
- 6 (Type: EXPERIMENTAL): atorvastatin 10mg + AVE5530 50mg
- 7 (Type: ACTIVE_COMPARATOR): atorvastatin 20mg
- 8 (Type: EXPERIMENTAL): atorvastatin 20mg + AVE5530 25mg
- 9 (Type: EXPERIMENTAL): atorvastatin 20mg + AVE5530 50mg
- 10 (Type: ACTIVE_COMPARATOR): atorvastatin 40mg
- 11 (Type: EXPERIMENTAL): atorvastatin 40mg + AVE5530 25mg
- 12 (Type: EXPERIMENTAL): atorvastatin 40mg + AVE5530 50mg
- 13 (Type: ACTIVE_COMPARATOR): atorvastatin 80mg
- 14 (Type: EXPERIMENTAL): atorvastatin 80mg + AVE5530 25mg
- 15 (Type: EXPERIMENTAL): atorvastatin 80mg + AVE5530 50mg

Based on this trial design, predict the completion outcome and termination type (if applicable).